Last mentioned: Mar 24, 2026
Brazil Patent Grant
INPI grants patent for Recce's anti-infectives platform.
Clinical Progress
Ongoing Phase I/II trials for RECCE® 327 in sepsis and burn wounds.
Global IP Expansion
Recce secures similar patent protections in the US, EU, and Japan.
Recce Pharmaceuticals has received a patent grant in Brazil for its synthetic anti-infective platform, marking a significant expansion of its intellectual property portfolio in South America. This move strengthens the company's global position in the fight against antimicrobial resistance (AMR), a critical challenge for modern healthcare.
Recce Pharmaceuticals has been granted a pivotal patent in Brazil for its proprietary synthetic anti-infectives platform, marking a strategic expansion into South America's largest healthcare market. This intellectual property milestone strengthens the company's global protection for its novel class of broad-spectrum antibiotics designed to combat the escalating threat of antimicrobial resistance.
Recce Pharmaceuticals has been granted a key patent in Brazil for its synthetic anti-infectives platform, covering the manufacturing process for its lead candidates. This move secures intellectual property protection in South America's largest economy, bolstering the company's global strategy against antimicrobial resistance.